Truist Securities has downgraded Incyte Corporation (NASDAQ:INCY), noting Jakafi’s (ruxolitinib) patent loss approaching in 2028. Jakafi is Incyte’s top-selling drug. It is indicated for polycythemia ...

Vijay K Iyengar, the EVP of $INCY, sold 2,682 shares of the company on 07-03-2025 for an estimated $182,805. We received data on the trade from a recent SEC filing ...

Incyte (INCY) shares have shown solid momentum over the past month, gaining 12% and delivering a 21% return over the past 3 months. The company continues to draw investor attention for its performance ...

We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Incyte Corp. (NASDAQ:INCY) is one of the best-performing on Monday. Incyte extended its winning ...

If spiders are your particular trigger, then look away now, but be aware that experts in the field of our eight-legged friends are warning everyone to keep windows firmly closed for the coming month ...

Incyte's stock has declined nearly 60% from all-time highs in 2017 due to market volatility, regulatory challenges, and increased competition. Despite the decline, Incyte reported strong financial ...